Merck: will not submit applications for cholesterol drug.

(CercleFinance.com) - Merck said on Thursday that it would not submit applications for regulatory approval for its experimental cholesterol-lowering drug anacetrapib.


The US drugmaker said the decision followed a thorough review of the clinical profile of anacetrapib, including discussions with external experts.

In August, a trial showed that the medecine only reduced relative risk by 9% on over 30,000 patients, leading analysts not to see a viable path forward for the drug to be used in a broad population of patients.

Copyright (c) 2017 CercleFinance.com. All rights reserved.